Afya (NASDAQ:AFYA – Get Free Report) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks reports.
A number of other research firms also recently issued reports on AFYA. JPMorgan Chase & Co. decreased their price objective on shares of Afya from $19.00 to $17.50 and set an “overweight” rating for the company in a report on Tuesday. Morgan Stanley raised shares of Afya from an “underweight” rating to a “cautious” rating and set a $12.60 price objective on the stock in a research report on Thursday. Wall Street Zen cut shares of Afya from a “buy” rating to a “hold” rating in a research note on Saturday, October 31st. Bradesco Corretora raised shares of Afya to an “outperform” rating and set a $17.00 target price for the company in a research report on Thursday, September 24th. Finally, Bank of America raised shares of Afya from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Thursday, October 29th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $15.18.
Read Our Latest Analysis on Afya
Afya Trading Down 0.5%
Shares of Afya stock opened at $10.50 on Tuesday. Afya has a 1 year low of $9.66 and a 1 year high of $16.16. The firm has a market cap of $984.06 million, a PE ratio of 6.40, a P/E/G ratio of 1.65 and a beta of 0.43. The stock has a fifty day moving average price of $13.40 and a 200-day moving average price of $14.14. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.20 and a quick ratio of 2.20.
Afya (NASDAQ:AFYA – Get Free Report) last released its earnings results on Friday, August 14th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.40 by $0.03. The company had revenue of $187.80 million for the quarter, compared to analysts’ expectations of $189.62 million. Afya had a return on equity of 17.58% and a net margin of 20.55%. Equities research analysts anticipate that Afya will post 1.72 EPS for the current year.
Insider Activity
In other Afya news, insider Santos Welder Ferreira sold 4,161 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $13.30, for a total value of $55,341.30. Following the sale, the insider directly owned 35,000 shares in the company, valued at $465,500. The trade was a 10.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.80% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Afya stock. Engineers Gate Manager LP acquired a new position in Afya Limited (NASDAQ:AFYA – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 21,882 shares of the company’s stock, valued at approximately $325,000. Institutional investors own 88.02% of the company’s stock.
About Afya
Afya Limited is a medical education and digital health company focused on Brazil. Through its educational platform, the company provides undergraduate medical education, medical residency preparation, specialization and continuing medical education programs, and other learning resources for students and physicians.
Afya also offers digital products and services intended to support healthcare professionals throughout their careers. These include clinical content, study tools, telemedicine and practice-management solutions, and subscription-based applications designed to assist physicians with education, clinical decision-making, and patient care.
The company has expanded through the development and acquisition of medical schools, education businesses, and health technology platforms serving different stages of the medical professional lifecycle.
See Also
- Five stocks we like better than Afya
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
